Romiplostim more effective than standard care for immune thrombocytopenia

A new study finds that an FDA-approved drug to treat the rare autoimmune disorder immune thromobocytopenia (ITP) is more effective than earlier medical therapies in helping patients avoid surgical treatment and significantly improving their quality of life. The paper in the Nov. 11 New England Journal of Medicine reports that treatment with romiplostim, which mimics the effects of a growth factor that regulates platelet production, was more than three times more successful than standard therapy with steroids or immunosuppressive drugs.

Read the whole article on Physorg

More from Physorg